You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.
Relmada Therapeutics raises $115M from stock offering
Gauging Supply Chain Risk In Volatile Times
Cannabis: Hashing Out a Budding Industry
IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help
The Market Intelligence Platform
Relmada Therapeutics Inc.
The New York-based pharmaceutical company offered 3,833,334 shares at $30 apiece, including 500,000 shares as part of underwriters' overallotment option.
Relmada intends to use the gross proceeds from the offering to fund the research and development of its treatment-resistant depression drug REL-1017, or dextromethadone, and for general corporate purposes.
Jefferies, SVB Leerink and Guggenheim Securities acted as joint book-running managers for the offering.